|
Mutation Information
|
Mutation Site
|
I64I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
PR |
|
Relevant Drug
|
darunavir;cobicistat;emtricitabine (FTC);tenofovir alafenamide (TAF) |
|
Country
|
USA |
Literature Information
|
PubMed PMID
|
31516033
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
AIDS research and human retroviruses |
|
Title
|
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. |
|
Author
|
Lathouwers E,Wong EY,Brown K,Baugh B,Ghys A,Jezorwski J,Mohsine EG,Van Landuyt E,Opsomer M,De Meyer S,AMBER and EMERALD Study Groups. |
|
Evidence
|
One of the three participants in the D/C/F/TAF arm had virus with an emerging secondary PI RAM I64I/L/M.
|
|
|
HIV Mutation Detail Information